JPMorgan keeps an Overweight rating on Roivant Sciences (ROIV) after the company co-hosted a webinar to set expectations for brepocitinib’s dermatomyositis pivotal readout in the the second half of 2025. The threshold for a successful outcome is “within reach” given the mechanism of action is already partially de-risked based on off-label usage and past trials of JAKi, the analyst tells investors in a research note. JPMorgan views the upcoming dermatomyositis catalyst positively, saying there is little recognition for brepocitinib in Roivant shares today.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- Roivant Sciences to hold an investor webinar
- Sarepta suspends Elevidys shipments, Supernus acquires Sage: Morning Buzz
- Pulmovant announces publication of PK, lung deposition data for mosliciguat
- Strategic Growth and Orphan Drug Success Drive Buy Rating for Roivant Sciences
- Roivant Sciences Reports Progress and Financial Results
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue